Powered by a $6.1 billion annual budget and prosecutorial alliance with the Federal Trade Commission (FTC), last month the U.S. Food and Drug Administration (FDA) simultaneously charged three cannabidiol (CBD) companies with violating the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 301, et seq. (FDA Act) and Federal Trade Commission Act, 15 U.S.C. Sections 41-58 (FTC Act) by placing unapproved and misbranded human drugs and adulterants and unapproved and unsafe animal drugs into interstate commerce; and making false or unsubstantiated health claims.

A wildly popular nutritional supplement and food additive, oil-based hemp derived products like CBD racked up $1.1 billion in 2018 domestic sales and, after the Agriculture Improvement Act of 2018 (Farm Bill) removed them from the Controlled Substance Act, 21 U.S.C. Sections 801, (1970) and Drug Enforcement Administration’s (DEA) clutches, 2019 hemp production and sales exploded.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]